Literature DB >> 21114372

Hyperandrogenic states in pregnancy.

N Kaňová1, M Bičíková.   

Abstract

Hyperandrogenic states in pregnancy are almost always the result of a condition that arises during pregnancy. The onset of virilization symptoms is often very fast. The mother is protected against hyperandrogenism by a high level of SHBG, by placental aromatase and a high level of progesterone. The fetus is protected from the mother's hyperandrogenism partly by the placental aromatase, that transforms the androgens into estrogens, and partly by SHGB. Nevertheless there is a significant risk of virilization of the female fetus if the mother's hyperandrogenic state is serious. The most frequent cause of hyperandrogenic states during pregnancy are pregnancy luteoma and hyperreactio luteinalis. Hormonal production is evident in a third of all luteomas, which corresponds to virilization in 25-35 % of mothers with luteoma. The female fetus is afflicted with virilization with two thirds of virilized mothers. Hyperreactio luteinalis is created in connection with a high level of hCG, e.g. during multi-fetus pregnancies. This condition most frequently arises in the third trimester, virilization of the mother occurs in a third of cases. Virilization of the fetus has not yet been described. The most serious cause of hyperandrogenism is represented by ovarian tumors, which are fortunately rare.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21114372     DOI: 10.33549/physiolres.932078

Source DB:  PubMed          Journal:  Physiol Res        ISSN: 0862-8408            Impact factor:   1.881


  18 in total

1.  Hyperreactio luteinalis encountered during caesarean delivery of an uncomplicated spontaneous singleton pregnancy.

Authors:  Inês Sarmento Gonçalves; Sofia Malafaia; Helena Belchior; Pedro Tiago-Silva
Journal:  BMJ Case Rep       Date:  2015-10-01

2.  Anogenital distance in newborn daughters of women with polycystic ovary syndrome indicates fetal testosterone exposure.

Authors:  E S Barrett; K M Hoeger; S Sathyanarayana; D H Abbott; J B Redmon; R H N Nguyen; S H Swan
Journal:  J Dev Orig Health Dis       Date:  2018-01-09       Impact factor: 2.401

Review 3.  Gestational Hyperandrogenism in Developmental Programming.

Authors:  Christopher Hakim; Vasantha Padmanabhan; Arpita K Vyas
Journal:  Endocrinology       Date:  2017-02-01       Impact factor: 4.736

Review 4.  Sex, stroke, and inflammation: the potential for estrogen-mediated immunoprotection in stroke.

Authors:  Rodney M Ritzel; Lori A Capozzi; Louise D McCullough
Journal:  Horm Behav       Date:  2012-04-24       Impact factor: 3.587

5.  Late presentation of hyperandrogenism in pregnancy: clinical features and differential diagnosis.

Authors:  Gautam Das; Vinay S Eligar; Jyothish Govindan; D Aled Rees
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2013-10-16

6.  RAPIDLY PROGRESSIVE AND SEVERE HIRSUTISM FROM HYPERREACTIO LUTEINALIS WITHIN A BACKGROUND OF POLYCYSTIC OVARY SYNDROME.

Authors:  Hannah Miriam Mathew; Christopher Wang Lee; Shirin Haddady
Journal:  AACE Clin Case Rep       Date:  2018-11-01

7.  Sildenafil augments fetal weight and placental adiponectin in gestational testosterone-induced glucose intolerant rats.

Authors:  Emmanuel Damilare Areola; Ifeoluwa Jesufemi Adewuyi; Taofeek Olumayowa Usman; God'sgift Tamunoibuomi; Lucy Kemi Arogundade; Barakat Olaoye; Deborah Damilayo Matt-Ojo; Abdulrazaq Olatunji Jeje; Adewumi Oluwafemi Oyabambi; Enoch Abiodun Afolayan; Lawrence Aderemi Olatunji
Journal:  Toxicol Rep       Date:  2021-06-30

8.  Virilisation during Pregnancy in a Patient with Metastatic Colorectal Cancer.

Authors:  F Conway; S Jarvis; M Thornton
Journal:  Case Rep Surg       Date:  2012-10-14

9.  Incidentally found hyperreactio luteinalis in pregnancy.

Authors:  Humara Edell; Omid Shearkhani; M Rose Rahmani; Rose C Kung
Journal:  Radiol Case Rep       Date:  2018-09-20

Review 10.  Androgens in pregnancy: roles in parturition.

Authors:  Sofia Makieva; Philippa T K Saunders; Jane E Norman
Journal:  Hum Reprod Update       Date:  2014-03-18       Impact factor: 15.610

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.